Hit enter to search or ESC to close
NuView Life SciencesNuView Life SciencesNuView Life SciencesNuView Life Sciences
  • Home
  • About Us
    • Mission
    • Leadership
      • Management Team
      • Directors
      • Clinical Collaborators
      • Consultants
  • Products
    • In Vivo Diagnostics
    • In Vitro Diagnostics
    • Theranostics Applications
    • Why Research for New Diagnostics?
  • Pipeline
  • News
    • NuView Life Sciences in the News
    • Press Releases
  • Publications
  • Contact Us
NuView Life Sciences
Monthly Archives

August 2020

Aug 25
Love2

Park City company develops new ground breaking cancer treatment

By Karla Jo Helms News

Park City company develops new ground breaking cancer treatment By Press Release August 25, 2020 283 0 Comments Park City— To meet the demand for…

Read More
Aug 20
Love1

FSP and COVID-19: Impact on Clinical Trial Development

By Karla Jo Helms News

BY CHRIS BAKER, SENIOR VICE PRESIDENT AND GLOBAL HEAD OF FSP, PAREXEL & JOANNE SULLIVAN, GLOBAL HEAD OF SAFETY AND REGULATORY OUTSOURCING, PAREXEL & LISA…

Read More
Aug 17
Love0

NuView NV-VPAC1 Uniquely Positioned to Find the Overexpression of Specific Receptors Appearing only on the Surface of Malignant Cells for Early Cancer Diagnosis

By Karla Jo Helms Press Releases

Cancer diagnosis and treatment need to be improved—and theranostics technology is working to bring a solution to market. NuView Life Sciences is focused on a…

Read More
Aug 04
Love0

NuView Life Sciences Secures $90 Million Capital Commitment from Global Emerging Markets for Development of NV-VPAC1™ Cancer Portfolio

By Karla Jo Helms Press Releases

PARK CITY, Utah (PRWEB)August 03, 2020 NuView Life Sciences, Inc. announced that it has signed an agreement with GEM Global Yield LLC SCS, a Luxembourg-based…

Read More

Categories

  • News
  • NuView Life Sciences in the News
  • Press Releases
  • Publications

Recent Posts

  • NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer
  • Targeting VPAC1 Receptors for Imaging Glioblastoma
  • NuView Life Sciences Creates Subsidiary for Latin American Market
  • Jay Bishoff, MD, joins The Smith Institute for Urology
  • Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

Archives

  • October 2022
  • January 2022
  • November 2021
  • August 2021
  • February 2021
  • January 2021
  • November 2020
  • August 2020
  • June 2020
  • May 2020
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • April 2019
  • March 2019
  • January 2019
  • November 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • March 2013
  • February 2013
  • February 2000
  • January 2000

NuView Life Sciences is a clinical stage oncology company addressing unmet medical needs.

Read More

Contact Address

NuView Life Sciences, Inc
1389 Center Drive, Suite 200
Park City, Utah 84098

Office: 435.647.9758 

Contact us:
admin@nuviewlifesciences.com

Media inquiries:
Jennifer K. Zimmons
jzimmons@zimmonsic.com

The most recent press

  • NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer October 5, 2022
  • NuView Life Sciences Creates Subsidiary for Latin American Market November 17, 2021

Quick Links

  • Home
  • About Us
  • Products
  • Pipeline
  • News
  • Publications

© 2023 NuView Life Sciences. Terms of Use

  • Home
  • About Us
    • Mission
    • Leadership
      • Management Team
      • Directors
      • Clinical Collaborators
      • Consultants
  • Products
    • In Vivo Diagnostics
    • In Vitro Diagnostics
    • Theranostics Applications
    • Why Research for New Diagnostics?
  • Pipeline
  • News
    • NuView Life Sciences in the News
    • Press Releases
  • Publications
  • Contact Us